ArticleEndocrine2019
The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice.
Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.Endocrine · 2026Pooled it
- Anti-resorptive agents in neuroendocrine bone metastases - A systematic review.Journal of bone oncology · 2026Review
- Challenges in the management of bone metastases: focus on differentiated thyroid cancer and neuroendocrine tumors.Journal of the Endocrine Society · 2026Article
- Impact on symptoms and survival of bone metastases in patients with small-intestinal neuroendocrine tumours.Journal of neuroendocrinology · 2025Article
- Non-functional, non-mutated multifocal neuroendocrine neoplasms in a postpartum female: a Case Report of an infrequent disease.Frontiers in medicine · 2025Article
- Factors Influencing Costs of Cancer Care for Patients with Neuroendocrine Neoplasms.Neuroendocrinology · 2025Review
- Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms.Journal of clinical medicine · 2023Article
- Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?Frontiers in medicine · 2023Review
- "The past is a different country, they do things differently there": using the SEER data-base to assess prognosis in neuroendocrine tumours.Endocrine · 2022Article
- Article
- Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021Review
- Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease.Endocrine · 2021Article
- Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the evolution and optimal management of metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs).
methodsSeventy-four patients were recruited from four NEN centers in this observational multicenter study.
resultsPancreas and small bowel were the most common primaries (30 and 27%, respectively). Almost all gastrointestinal (GI)-NENs were grades 1 and 2, whereas bronchopulmonary-thymic were atypical carcinoids. Thirty-two (43%) patients had synchronous metastatic bone disease (mBD) and three patients reported bone-specific symptoms; metachronous mBD developed at a median of 35 (range: 4-395) months. Thirty-six (86%) of patients with metachronous mBD had stage IV disease at diagnosis. Somatostatin receptor functional imaging and computed tomography were the modalities mostly used for mBD identification. Fifty-two patients received assessable bone-related therapy (bisphosphonates, denosumab, local radiotherapy, and radionuclide treatment). Improvement in mBD was seen in 5, stable disease in 22, and deterioration in 25 patients. The presence of synchronous mBD and the negative outcome of bone-related therapy negatively affected overall survival (OS). In the multivariate analysis, the stronger predictor of OS was the outcome of bone-related therapy (HR: 4.753; 95% CI: 1.589-14.213). Bisphosphonates therapy was the mostly used bone-specific treatment but its monthly administration did not affect OS. At last follow-up, 39 patients were alive with OS 50 (14-463) months.
conclusionsEarly investigation for mBD offers a prognostic marker of patients with NENs, since synchronous mBD has a negative impact on survival. The outcome of bone-related therapy affects OS but the monthly administration of bisphosphonates did not show a benefit over less intense schemes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.